LEXINGTON, Mass., March 2, 2021 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that James Dentzer,
President and Chief Executive Officer of Curis, will present a
company overview at the H.C. Wainwright & Co. Global Life
Sciences Conference. A pre-recorded presentation will be available
for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.
A webcast of the presentation will be available under "Events
& Presentations" in the Investors section of the Company's
website at www.curis.com. A replay of the webcast will be available
on the Curis website for approximately 90 days following the
About Curis, Inc.
Curis is a biotechnology company focused on the development of
innovative therapeutics for the treatment of cancer. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently
undergoing testing in a Phase 1 trial in patients with
non-Hodgkin's lymphoma both as a monotherapy and in combination
with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in
a Phase 1 trial in patients with acute myeloid leukemia and
myelodysplastic syndromes. In addition, Curis is engaged in a
collaboration with ImmuNext for development of CI-8993, a
monoclonal anti-VISTA antibody, which is currently undergoing
testing in a Phase 1a/1b trial in
patients with solid tumors. Curis is also party to a collaboration
with Genentech, a member of the Roche Group, under which Genentech
and Roche are commercializing Erivedge® for the treatment of
advanced basal cell carcinoma. For more information, visit Curis'
website at www.curis.com.
View original content to download
SOURCE Curis, Inc.